Atomoxetine exposure in a composite CYP2D6 intermediate metabolizer is predicted, hedged and then tested against phenoconversion in this MN660 Unit 9 pharmacogenomics summary. Searches like "mn 660 unit 9 assignment example", "mn660 unit 9 sample" and "mn660 unit 9 example" land here.
A CYP2D6 Intermediate Metabolizer Result Read as a Probability: Atomoxetine and Genotype *4/*41
[Student Name]
Purdue University Global
MN660: PMHNP Neuroscience and Psychopharmacology
Unit 9 Assignment
[Instructor Name]
[Date]
Composite patient written as a model document. The regimen is bracketed; no dosing is reproduced, and any regimen decision is left to the prescriber.
The Result as Reported
Genotype: CYP2D6 *4/*41. Activity score: 0.5. Predicted phenotype: intermediate metabolizer.
Section 1: From Genotype to Phenotype
Each CYP2D6 allele is assigned an activity value. The *4 allele produces no functional enzyme, activity 0; the *41 allele produces reduced function, activity 0.5. The two values are summed to an activity score, here 0.5. Under the 2020 consensus of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group, scores are mapped to phenotypes as follows (Caudle et al., 2020):
Activity score 0: poor metabolizer.
0.25 to 1.0: intermediate metabolizer.
1.25 to 2.25: normal metabolizer.
Above 2.25: ultrarapid metabolizer.
The same consensus moved a score of 1.0 from normal to intermediate metabolizer, so labels issued before 2020 may differ from current ones for some genotypes. Her score of 0.5 falls within the intermediate range under either version.
Section 2: Why Atomoxetine Depends on This Enzyme
Atomoxetine is a selective norepinephrine reuptake inhibitor used for ADHD. It is cleared mainly by CYP2D6 to 4-hydroxyatomoxetine. The product labeling reports that people who are poor metabolizers have roughly tenfold higher exposure than extensive metabolizers at the same dose (Eli Lilly and Company, 2022). An intermediate metabolizer is likely to have exposure between those extremes, higher than a normal metabolizer but lower than a poor one. Higher exposure is expected to bring more of the drug's known effects, such as raised heart rate and blood pressure, insomnia and decreased appetite.
Section 3: What the Guideline Says
The 2019 CPIC guideline for CYP2D6 and atomoxetine provides phenotype-specific recommendations for starting doses and for when to consider checking drug levels, with different approaches for poor, intermediate, normal and ultrarapid metabolizers (Brown et al., 2019). This summary does not reproduce the amounts, which belong to the prescriber and to the current version of the guideline. The guideline is dated because CPIC guidance is revised as evidence accumulates.
Section 4: Why the Label Is a Probability
Four things could make the label wrong for her.
Untested alleles. Panels test a set list of alleles. A rare allele not on the panel would be reported as the default, usually *1, which could overstate her enzyme activity.
Duplications and hybrids. Some people carry extra copies of CYP2D6 or hybrid genes with the neighboring CYP2D7. Not every panel detects these, and a missed duplication could understate her activity.
Phenoconversion. A strong CYP2D6 inhibitor can make a genotypic intermediate metabolizer behave like a poor metabolizer. In a bracketed scenario, [fluoxetine added] for depression, her functional CYP2D6 activity would likely fall close to zero, and her atomoxetine exposure would be expected to rise toward that of a poor metabolizer. Paroxetine and bupropion would have a similar effect.
Other factors. Liver disease, age and other medicines also affect exposure, independent of genotype.
Conclusion
Her result means she is likely to clear atomoxetine more slowly than average and may be expected to have higher exposure at a standard dose. It does not guarantee it. The result should be read alongside her other medicines, and any regimen decision is left to her prescriber.
References
Brown, J. T., Bishop, J. R., Sangkuhl, K., Nurmi, E. L., Mueller, D. J., Dinh, J. C., Gaedigk, A., Klein, T. E., Caudle, K. E., McCracken, J. T., de Leon, J., & Leeder, J. S. (2019). Clinical Pharmacogenetics Implementation Consortium guideline for cytochrome P450 (CYP)2D6 genotype and atomoxetine therapy. Clinical Pharmacology & Therapeutics, 106(1), 94-102. https://doi.org/10.1002/cpt.1409
Caudle, K. E., Sangkuhl, K., Whirl-Carrillo, M., Swen, J. J., Haidar, C. E., Klein, T. E., Gammal, R. S., Relling, M. V., Scott, S. A., Hertz, D. L., Guchelaar, H.-J., & Gaedigk, A. (2020). Standardizing CYP2D6 genotype to phenotype translation: Consensus recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clinical and Translational Science, 13(1), 116-124. https://doi.org/10.1111/cts.12692
Eli Lilly and Company. (2022). Strattera (atomoxetine) capsules: Prescribing information. Eli Lilly and Company.
How this MN660 Unit 9 example is structured
The composite result opens the summary as it would appear on a report, genotype, activity score and predicted phenotype on three lines, which puts the thing under interpretation in plain view. Each section then answers one question in order: how the label was derived, why this drug depends on this enzyme, what the published guideline says about the phenotype, and what could make the label wrong for her. The table sets out activity score bands and their phenotypes with the consensus source. Uncertainty is written into the prose rather than appended: every predictive sentence carries a qualifier such as likely or expected, and the phenoconversion paragraph uses a bracketed scenario, [fluoxetine added], to show a genotypic intermediate behaving as a poor metabolizer. The conclusion restates the result as a likelihood and leaves any regimen decision to the prescriber. Citations are dated, since CPIC guidance is revised.
Get an MN660 Unit 9 example written to your instructions
Pharmacogenomics prompts differ in the gene and drug they name, so include yours, or leave the pair to us, with the rubric. A first summary, free and built to those instructions within 24-48h, derives the phenotype step by step, cites dated CPIC guidance narrowly, and states every prediction as a likelihood, including what could change it. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
MN660 Unit 9 questions, answered
Which CPIC guideline should I cite?
The one for your specific gene and drug pair, with its publication year. CPIC publishes separate guidelines, for example on CYP2D6 and atomoxetine in 2019 and on SSRIs in 2023, and updates them over time. Citing the consortium in general without a guideline, or an older version when a newer one exists, is a precision error graders tend to catch.
What is phenoconversion, and does the summary need it?
It is the mismatch between genotype and actual enzyme activity caused by other factors, most often a strong inhibiting drug. A person genotyped as a normal metabolizer who takes paroxetine may clear CYP2D6 substrates like a poor metabolizer. Most sections expect it, because it is the clearest illustration of why the label on a report is an estimate.
Should the summary discuss testing costs or access?
Rarely; the prompt would have to raise them. This unit usually concerns what a result means pharmacologically, not whether a test should be ordered. A sentence acknowledging that panels vary in which alleles they test is relevant, since it affects interpretation, but debates about coverage and cost are a policy question for another assignment.